ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0075

Association of Obesity with 3-Month COVID-19-Related Mortality in ESKD Patients

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Tantisattamo, Ekamol, Harold Simmons Center for Kidney Disease Research and Epidemiology, Division of Nephrology, Hypertension and Kidney Transplantation, Department of Medicine, University of California Irvine School of Medicine, Orange, California, United States, Orange, California, United States
  • Imhof, Céline, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Groningen, Netherlands
  • Hilbrands, Luuk, Department of Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands., Groningen, Netherlands
  • Jager, Kitty J., ERA-EDTA Registry, Department of Medical Informatics, Amsterdam University Medical Center, Amsterdam Public Health Research Institute, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands., Amsterdam, Netherlands
  • Noordzij, Marlies, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Groningen, Netherlands
  • Vart, Priya, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Groningen, Netherlands
  • Kalantar-Zadeh, Kamyar, Harold Simmons Center for Kidney Disease Research and Epidemiology, Division of Nephrology, Hypertension and Kidney Transplantation, Department of Medicine, University of California Irvine School of Medicine, Orange, California, United States, Orange, California, United States
  • Gansevoort, Ron T., Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Groningen, Netherlands
Background

In the general population obesity is associated with increased risk of mortality. However, in ESKD patients obesity is associated with lower risk of mortality, particularly in dialysis patients (i.e. the obesity paradox). In COVID-19 patients, obesity exhibits a similar association with mortality as observed in the non-COVID-19 general population. Given the obesity paradox, we questioned the association of obesity with mortality in ESKD patients with COVID-19.

Methods

Data from the European Renal Association COVID-19 Database (ERACODA) were analysed. Association of BMI (kg/m2), divided into: <18.5 (lean), 18.5-24.9 (normal weight), 25-29.9 (overweight), 30-34.9 (obese I) and ≥35 (obese II), with 3-month mortality was investigated using Cox proportional-hazards regression. Results were investigated for the total population and, dialysis patients and kidney transplant recipients separately.

Results

In 3160 ESKD patients (mean age: 65 years, male: 61%), 99 patients were lean, 1151 normal weight (reference group), 1160 overweight, 525 obese I and 225 obese II. During follow-up of 3 months, 28%, 20%, 21%, 23% and 27% of patients died in the lean, normal weight, overweight, obese I and obese II category, respectively. In fully adjusted model, the HRs for 3-month mortality were 1.65 (95% CI:1.10, 2.47), 1.07 (95% CI:0.89, 1.28), 1.17 (95% CI:0.93, 1.46) and 1.71 (95%CI:1.27, 2.30) in lean, overweight, obese I and obese II vs normal weight patients (Figure). Results were similar among dialysis patients and transplant recipients (p-interaction=0.99).

Conclusion

In ESKD patients with COVID-19, dialysis patients or kidney transplant recipients, obesity is associated with an increased risk of mortality at 3 months. This is contrary to obesity paradox generally observed in dialysis patients. There is need to investigate why in dialysis patients with COVID-19 the survival benefit of obesity is lost.

Funding

  • Commercial Support